All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Cystic echinococcosis (CE) is a neglected parasitic zoonosis caused by infection with the cestode *Echinococcus granulosus sensu lato* species complex. The parasite is endemic worldwide, especially prevalent in areas where livestock breeding is practiced \[[@pntd.0008519.ref001]\]. It is naturally transmitted between canids, definitive hosts harbouring the adult cestodes in the intestine and shedding parasite eggs with the faeces, and livestock, intermediate hosts getting infected upon ingestion of parasite eggs, where the larval stage (metacestode) develops in the form of fluid-filled cysts in liver, lungs and other organs. The definitive hosts in turn acquire the infection by eating parasite cysts in infected organs of slaughtered animals. Humans act as accidental, dead-end intermediate hosts, acquiring the infection through ingestion of parasite eggs and developing echinococcal cysts mostly in the liver, followed by lungs \[[@pntd.0008519.ref002]\].

*E*. *granulosus s*.*l*. is particularly prevalent in China and Central Asia, South America, North and East Africa, and Australia; in Europe, another endemic area, it is especially present in the Mediterranean and Eastern countries, its cycle mainly involving domestic dogs and ruminants (sheep, goats, cattle) \[[@pntd.0008519.ref001]\]. CE is responsible for significant economic losses in the public health sector. At global level, Budke and colleagues \[[@pntd.0008519.ref003]\] estimated a human burden of around 1 million Disability-Adjusted Life Years (DALYs) and 760 million US\$ losses due to human infection (accounting for underreporting), and annual livestock production losses of at least US\$ 140 million. For what concerns Europe, in Italy, based on Hospital Discharge Records (HDR), Piseddu and colleagues \[[@pntd.0008519.ref004]\] estimated a financial burden due to human CE of around € 53 million in 2001--2014, with a national average economic burden of € 4 million per year. In Spain, Benner and colleagues \[[@pntd.0008519.ref005]\] estimated, for the year 2005, and overall economic loss due to human and livestock CE of about € 150 million, of which about 130 million were human-associated and about 16 million animal-associated.

However, the real health and economic burden due to CE are difficult to estimate. On the one hand, animal infection is not perceived as an infection of high concern, and presence and implementation of structured surveillance of infection in animals is variable among and within countries \[[@pntd.0008519.ref006]\]. On the other hand, human CE is a chronic, disabling condition, its clinical manifestations ranging from asymptomatic infection to extremely severe disease, and costs for its treatment may be substantial. However, again, presence and type of disease notification systems vary greatly from country to country, and mostly include only hospitalized cases \[[@pntd.0008519.ref006]\]. This situation results in poor accuracy, and likely large underestimate, of the epidemiological parameters of CE distribution, costs, and socio-economic burden. This in turn contributes to the neglect of CE, with subsequent little focus on accurate and representative data collection, feeding a vicious circle of data inaccuracy, underestimation, and neglect.

Here, we carried out a systematic review of the literature on *E*. *granulosus s*.*l*. infection prevalence and incidence data in European Mediterranean and Balkan countries between 2000 and 2019, in both humans and animals, in an attempt to provide a picture of recent animal and human CE epidemiology in Europe, and their relation. This geographical area, where *E*. *granulosus s*.*l*. is endemic, was chosen on the basis of relative homogeneity of climate and livestock breeding practices.

Materials and methods {#sec002}
=====================

Search strategy {#sec003}
---------------

The research question of the study concerned the current epidemiological situation, in terms of incidence and/or prevalence of human, canine, and domestic ruminant hosts, in European Mediterranean and Balkan countries. A literature search was carried out to identify all possible studies that could help to answer the research question. The following databases were searched for relevant studies: MEDLINE (PubMed) (1966 to October 19^th^ 2019) and EMBASE (1974 to October 19^th^ 2019). The detailed strategy is available as Supplementary Information [S1 Text](#pntd.0008519.s002){ref-type="supplementary-material"}. Additional sources were searched up to October 2019: Google Scholar, Scopus, and Open Grey were used to identify articles that cited relevant reports using free-text terms ("cystic echinococcosis", "hydatidosis", "Echinococcus granulosus"). For Google Scholar, Scopus, and Open Grey, the first 500 search results, sorted by date, were considered; this arbitrary number was chosen as it reasonably included all relevant results for the investigated time frame. The reference lists of reviews and relevant reports were also searched to identify additional studies. Search results were combined and duplicates removed before screening for relevance. No restriction was applied regarding language or publication status (published or in press). The search was initially performed on papers published from January 1^st^ 1980, however, due to the difficulty in extracting data from literature published during '80 and '90, eventually only papers published from January 1^st^ 2000 onwards were included in the analysis. Among these, retrospective studies reporting data from investigations starting before 1980 were also excluded. The work is presented according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA <http://prisma-statement.org/prismastatement/Checklist.aspx>, [S1 PRISMA](#pntd.0008519.s001){ref-type="supplementary-material"} Check list).

Population, inclusion and exclusion criteria, study design, and outcomes {#sec004}
------------------------------------------------------------------------

Original cross-sectional and longitudinal studies, as well as case series, reporting prevalence or incidence of human or animal (ovine, bovine, and canine) *E*. *granulosus s*.*l*. infection were included in this review; case reports and review articles were excluded. Papers reporting data from the following European Mediterranean and Balkan countries were included (from West to East): Portugal, Spain, France, Italy, Slovenia, Serbia, Croatia, Bosnia-Herzegovina, Montenegro, Macedonia, FYROM (Former Yugoslav Republic Of Macedonia), Republic of North Macedonia, Kosovo, Albania, Greece, Romania, Bulgaria and Cyprus. No restriction was applied regarding publication type (e.g. research paper or conference report) or setting (e.g. field or clinical setting). For human studies, only cases reported from HDR or hospital databases, or confirmed by histopathology, or based on imaging studies, were included; surveys based on serology only were excluded due to the poor performance of serology for CE in population studies \[[@pntd.0008519.ref007]\]. For dog studies, necropsy and coprological studies based on microscopy, PCR or copro-ELISA were included. For ruminants, studies based on pathological examination after slaughter were included. Extracted and analyzed study outcomes were prevalence or incidence of *E*. *granulosus s*.*l*. infection based on reported incidence or, when available, on reported cases (numerator) and size of the at risk population (denominator).

Study selection and data extraction {#sec005}
-----------------------------------

Two authors (FT and ML for human studies and ML and MD for animal studies) reviewed titles and abstracts of publications identified by the search, in order to identify all studies that potentially met the inclusion criteria. After having obtained the full text, the two authors independently assessed whether the study was eligible for inclusion. Potentially eligible studies were excluded if: 1) full text and abstract were both unavailable or only the abstract was available but did not convey the needed data; 2) infection cases (numerator) and size of the studied population (denominator) or calculated incidence/prevalence were not extractable; 3) diagnostic method was not mentioned or not eligible; 4) *E*. *granulosus s*.*l*. was not investigated or the species of *Echinococcus* was not specified; 5) study duplication. The same two authors performed the data extraction using a pre-designed Excel data extraction sheet. At all steps, when the two authors disagreed and did not reach a consensus after discussion, a third author (RC) facilitated the discussion and eventually made the final decision. The following data were extracted: country and geographical area investigated, at NUTS1 (Nomenclature of Territorial Units for Statistics) and NUTS2 level \[[@pntd.0008519.ref008]\], date and type of study (cross-sectional, prospective or retrospective case cohorts and case series), host species investigated, type of epidemiological parameter (prevalence or incidence) measured, diagnostic method, case numbers (numerator) and studied population (denominator) or calculated incidence, and type of studied population (general or specific setting/subpopulation). The decision to refer extracted data to the NUTS level was due to the need of clustering data in regions of comparable size, at least in terms of human population. The NUTS classification is a hierarchical system for dividing the territory of the European countries. Each country is composed by one or more major regions (NUTS1 level) and each NUTS1 is divided in different NUTS2 areas. According to NUTS regulation, minimum and maximum population thresholds for the size of NUTS1 and NUTS2 levels are 3,000,000--7,000,000 and 800,000--3,000,000, respectively. The study area consisted of 46 NUTS1 and 110 NUTS2 (French and Portuguese overseas territories were not considered).

Data analysis and synthesis {#sec006}
---------------------------

The human CE dataset ([S1 Table](#pntd.0008519.s003){ref-type="supplementary-material"}) was organized by extracting the data from all eligible papers at the level of NUTS2 for what concerns the spatial aspect and considering the timeframe of one year. This was considered as the epidemiological unit. Data from publications investigating different years and/or different NUTS2 were divided in as many epidemiological units as appropriate. Therefore each row of the dataset reported the data of a single epidemiological unit (i.e. NUTS2 level in a given year), in terms of prevalence, incidence, number of cases (numerator), and/or total population at risk (denominator).

For human case series, when both incidence rate and number of cases were reported, the population at risk was calculated. If data reported in multi-year retrospective case series of human CE were not differentiated for each year, a single value was inserted in the dataset, corresponding to an average annual incidence. If the NUTS2 level was not specified, data were referred to the NUTS1 level, and if also the NUTS1 specification was absent, data were referred to the national level. To estimate incidence at NUTS1 level, the average of all values reported for all epidemiological units belonging to the same NUTS1 was calculated.

In studies where human infection was investigated through a cross-sectional survey, the sum of positive cases (numerator) and tested individuals (denominator) was calculated for each epidemiological unit. To merge data from different epidemiological units at NUTS1 level, the pooled prevalence and 95% Confidence Interval (CI) were estimated, based on the inverse variance method and logit transformation \[[@pntd.0008519.ref009]\] to account for study weight with respect to population size (i.e. sampling fraction) and variance effect (i.e. prevalence very low or very high).

Similarly, the animal infection dataset ([S2 Table](#pntd.0008519.s004){ref-type="supplementary-material"}) was organized spatially at the level of NUTS2 and considering the timeframe of one year, keeping separately the different host species investigated (dog, cattle, sheep). The data analysis was carried out as described above, for prevalence estimation.

Data management and elaboration were performed in Excel 14.7.7 (Microsoft Corporation, Redmond, WA).

Results {#sec007}
=======

Bibliographic search {#sec008}
--------------------

The search and selection of included studies is shown in [Fig 1](#pntd.0008519.g001){ref-type="fig"}. The database search effectuated on February 19^th^, 2018 retrieved a total of 811 publications. After duplicates were removed, 572 records were further filtered by year of publication, leaving 471 papers published on or after the year 2000. The literature search re-launched on October 28^th^, 2019 retrieved further 24 records; further 5 potentially eligible studies published on or after year 2000 were retrieved from the bibliography lists of reviews. A total of 500 records were therefore screened for potential eligibility by title and abstract, of which 103 were selected for full-text review: 37 on human infection, 8 on both human and animal infection, and 58 on animal infection. Of these, 24 were further excluded, leaving 79 publications from which data were extracted: 25 on human infection and 54 on animal infection. It was not possible to extract data for both human and animal infections from those studies investigating the two aspects at the same time.

![Flow diagram of the literature search.](pntd.0008519.g001){#pntd.0008519.g001}

Human infection {#sec009}
---------------

Data extracted from the 25 publications on human infection were covering 7 eligible countries. All but two papers \[[@pntd.0008519.ref010],[@pntd.0008519.ref011]\] were retrospective case series: hospitalized cases (n = 15) based on HDR, or based on clinical records of cases who reached clinical attention (n = 6), or surgical cases (n = 2). The above mentioned two papers were abdominal ultrasound-based cross-sectional surveys, conducted on the rural populations of three countries, among which two were eligible for our study (Romania and Bulgaria).

The 23 retrospective case series studies were mostly reporting multi-year data: 14 papers recorded incidence values for each year, in eight publications a single incidence value was reported for the whole period, and one study investigated a 1-year period. In seven papers only the incidence value was reported, in 15 both the number of new cases and the incidence values, while only in one paper the population at risk was also explicitly reported (around 650,000 people, population of Timis County in Romania--found in the NUTS1 RO4). Overall, extracted data were separated in 430 epidemiological units, distributed in 33 NUTS1. The average incidence for each NUTS1 is reported in [Table 1](#pntd.0008519.t001){ref-type="table"}, together with the lowest and highest values, if more than one epidemiological unit were present in the same NUTS1. In these cases, the type of data aggregation is specified, namely multi-years if different (usually subsequent) years of the same NUTS2 were included in the study, or multi-area if different NUTS2 were assessed. The spatial distribution of the incidence values is shown in [Fig 2](#pntd.0008519.g002){ref-type="fig"}.

![Spatial distribution of average human incidence rates.\
Average incidence values at NUTS1 level are visualised with progressively intense colours according to ranges established by Jenks optimization method and manually adjusted for a better results visualisation. Data at country level are reported only if more detailed data at NUTS1 level were not available (source of NUTS shapefiles: Eurostat).](pntd.0008519.g002){#pntd.0008519.g002}

10.1371/journal.pntd.0008519.t001

###### Mean human annual incidence (n/100,000) of CE at NUTS1 level.

![](pntd.0008519.t001){#pntd.0008519.t001g}

  Country        NUTS1 code                                  N epidem. units   Years[^a^](#t001fn002){ref-type="table-fn"}   Data aggregation[^b^](#t001fn003){ref-type="table-fn"} (MY: multi-years; MA: multi-areas)   Mean annual incidence (n/100,000)   Min    Max     References
  -------------- ------------------------------------------- ----------------- --------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------- ------ ------- --------------------------------------------------------------------------------------------------
  **Portugal**                                               **1**                                                                                                                                                                                                          
                 PT1                                         1                 2004--2008                                                                                                                                **3.20**                                           \[[@pntd.0008519.ref012]\]
  **Spain**      ** **                                       **124**                                                         ** **                                                                                                                                          
                 ES1                                         12                1998--2012                                    MY and MA                                                                                   **0.50**                            0.00   1.04    \[[@pntd.0008519.ref013],[@pntd.0008519.ref014]\]
                 ES2                                         27                1998--2012                                    MY and MA                                                                                   **2.71**                            0.00   7.38    \[[@pntd.0008519.ref013]--[@pntd.0008519.ref015]\]
                 ES3                                         2                 1998--2012                                    MA                                                                                          **2.30**                            1.99   2.60    \[[@pntd.0008519.ref014]\]
                 ES4                                         49                1996--2012                                    MY and MA                                                                                   **7.74**                            1.49   20.30   \[[@pntd.0008519.ref013],[@pntd.0008519.ref014],[@pntd.0008519.ref016]--[@pntd.0008519.ref019]\]
                 ES5                                         18                1998--2012                                    MY and MA                                                                                   **0.62**                            0.05   1.77    \[[@pntd.0008519.ref013],[@pntd.0008519.ref014]\]
                 ES6                                         14                1998--2012                                    MY and MA                                                                                   **1.25**                            0.00   3.63    \[[@pntd.0008519.ref013],[@pntd.0008519.ref014]\]
                 ES7                                         2                 1998--2012                                    MA                                                                                          **0.16**                            0.12   0.19    \[[@pntd.0008519.ref014]\]
  **France**                                                 **22**                                                                                                                                                                                                         
                 FR1                                         1                 2005--2014                                                                                                                                **0.51**                                           \[[@pntd.0008519.ref020]\]
                 FRB                                         1                 2005--2014                                                                                                                                **0.20**                                           \[[@pntd.0008519.ref020]\]
                 FRC                                         2                 2005--2014                                    MA                                                                                          **0.47**                            0.35   0.59    \[[@pntd.0008519.ref020]\]
                 FRD                                         2                 2005--2014                                    MA                                                                                          **0.21**                            0.12   0.29    \[[@pntd.0008519.ref020]\]
                 FRE                                         2                 2005--2014                                    MA                                                                                          **0.19**                            0.18   0.19    \[[@pntd.0008519.ref020]\]
                 FRF                                         3                 2005--2014                                    MA                                                                                          **0.54**                            0.52   0.57    \[[@pntd.0008519.ref020]\]
                 FRG                                         1                 2005--2014                                                                                                                                **0.18**                                           \[[@pntd.0008519.ref020]\]
                 FRH                                         1                 2005--2014                                                                                                                                **0.10**                                           \[[@pntd.0008519.ref020]\]
                 FRI                                         3                 2005--2014                                    MA                                                                                          **0.24**                            0.13   0.40    \[[@pntd.0008519.ref020]\]
                 FRJ                                         2                 2005--2014                                    MA                                                                                          **0.40**                            0.31   0.49    \[[@pntd.0008519.ref020]\]
                 FRK                                         2                 2005--2014                                    MA                                                                                          **0.46**                            0.31   0.61    \[[@pntd.0008519.ref020]\]
                 FRL                                         1                 2005--2014                                                                                                                                **0.85**                                           \[[@pntd.0008519.ref020]\]
                 FRM                                         1                 2005--2014                                                                                                                                **1.76**                                           \[[@pntd.0008519.ref020]\]
  **Italy**                                                  **254**                                                                                                                                                                                                        
                 IT0[^c^](#t001fn004){ref-type="table-fn"}   2                 2001--2014                                    MY                                                                                          **1.92**                            1.06   2.78    \[[@pntd.0008519.ref004]\]
                 ITC                                         48                2001--2012                                    MY and MA                                                                                   **0.55**                            0.00   1.60    \[[@pntd.0008519.ref021]\]
                 ITH                                         49                1997--2012                                    MY and MA                                                                                   **0.37**                            0.00   1.13    \[[@pntd.0008519.ref021],[@pntd.0008519.ref022]\]
                 ITI                                         48                2001--2012                                    MY and MA                                                                                   **1.02**                            0.06   2.79    \[[@pntd.0008519.ref021]\]
                 ITF                                         72                2001--2012                                    MY and MA                                                                                   **2.76**                            0.42   10.80   \[[@pntd.0008519.ref021]\]
                 ITG                                         35                1998--2012                                    MY and MA                                                                                   **6.41**                            3.48   11.90   \[[@pntd.0008519.ref021],[@pntd.0008519.ref023]--[@pntd.0008519.ref025]\]
  **Greece**                                                 **2**                                                                                                                                                                                                          
                 EL0[^d^](#t001fn005){ref-type="table-fn"}   2                 1999--2000                                    MY                                                                                          **0.37**                            0.28   0.45    \[[@pntd.0008519.ref026]\]
  **Romania**                                                **10**                                                                                                                                                                                                         
                 RO1                                         1                 2000--2010                                                                                                                                **5.70**                                           \[[@pntd.0008519.ref027]\]
                 RO4                                         9                 1991--2008                                    MY and MA                                                                                   **4.39**                            2.40   7.16    \[[@pntd.0008519.ref028]--[@pntd.0008519.ref031]\]
  **Bulgaria**                                               **17**                                                                                                                                                                                                         
                 BG0[^e^](#t001fn006){ref-type="table-fn"}   7                 2006--2012                                    MY                                                                                          **4.85**                            3.85   6.28    \[[@pntd.0008519.ref032]\]
                 BG3                                         9                 2009--2013                                    MY                                                                                          **4.67**                            1.80   6.6     \[[@pntd.0008519.ref032]\]
                 BG4                                         1                 2006--2014                                                                                                                                **3.58**                                           \[[@pntd.0008519.ref033]\]
  **Total**                                                  **430**                                                                                                                                                                                                        

NUTS1 codes explanation is provided in Supplementary Information [S3 Table](#pntd.0008519.s005){ref-type="supplementary-material"}. NUTS1 with "0" after the two-letters initials of the country refers to the whole country. Minimum and maximum values are reported only for NUTS1 within which more than one epidemiological unit were investigated.

^a^Years refers to the overall time frame of all included studies.

^b^MY indicates NUTS1 whose mean incidence was calculated, based on one/more studies providing data for each single year. It does not include single studies covering more years, but providing only the overall annual mean.

^c^The paper reports data for the whole country for the first (2001) and last year (2014) of the survey.

^d^The paper does not specify the reference population, but likely refers to the whole country.

^e^These data refer to the whole country.

Overall, the two papers based on abdominal ultrasound-based surveys covered 4 NUTS1 and 7 epidemiological units. The pooled prevalence and 95% CI of the two cross-sectional surveys are reported in [Table 2](#pntd.0008519.t002){ref-type="table"}.

10.1371/journal.pntd.0008519.t002

###### Human pooled prevalence at NUTS1 level.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country        NUTS1 code   N epidem. units   Years[^a^](#t002fn002){ref-type="table-fn"}   Total positive humans   Total tested humans   Pooled prevalence (%)   CI95% min\   CI95% max\   References
                                                                                                                                                                    (%)          (%)          
  -------------- ------------ ----------------- --------------------------------------------- ----------------------- --------------------- ----------------------- ------------ ------------ ---------------------------------------------------
  **Romania**                 **3**                                                                                                                                                           

                 RO2          2                 2014--2015                                    15                      4,254                 **0.35**                0.21         0.58         \[[@pntd.0008519.ref010]\]

                 RO3          1                 2014--2015                                    20                      3,207                 **0.62**                0.40         0.96         \[[@pntd.0008519.ref010]\]

  **Bulgaria**                **4**                                                                                                                                                           

                 BG3          2                 2014--2015                                    10                      3,115                 **0.32**                0.17         0.60         \[[@pntd.0008519.ref010]\]

                 BG4          2                 2014--2015                                    23                      6,129                 **0.35**                0.21         0.58         \[[@pntd.0008519.ref010],[@pntd.0008519.ref011]\]

  **Total**                   **7**                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NUTS1 codes explanation is provided in Supplementary Information [S3 Table](#pntd.0008519.s005){ref-type="supplementary-material"}.

^a^Years refers to the overall time frame of all included studies.

Animal infection {#sec010}
----------------

Among the 54 publications on animal infection, only 3 studies (all conducted in Italy) investigated the three target species (cattle, sheep, dogs) at the same time, 14 studies focused on both intermediate hosts, 9 only on cattle, 9 only on sheep and 19 papers dealt specifically with the definitive host.

Studies focusing on the intermediate hosts were one-year or multi-years prevalence studies generally based on slaughterhouse records of visual inspection results; only in one case, species identification was confirmed by molecular analysis. Dog populations were investigated by cross-sectional surveys in all but one study, which had a prospective longitudinal design; to make results of this study comparable with those of the other studies, only baseline data were extracted. Many different diagnostic techniques were applied, including flotation copromicroscopy or taeniid eggs isolation complemented by PCR for species identification, coproELISA, coproPCR, and necroscopic examination (variably including intestinal mucosa scraping and other poorly specified techniques).

Finally, regarding animal characteristics and subpopulations, in most cases no specific information was provided on sheep and cattle, with the exception of four studies where only adult animals (sheep \>2 or 3 years; cattle \>2 or 5 years) were included. Investigated dogs, instead, were usually selected according to their role or lifestyle, and the most frequent category was sheep dogs (n = 8), followed by stray or free-ranging dogs (n = 7). In a few cases also bovine farm dogs (n = 3), hunting dogs (n = 3) and pet dogs (n = 1) were included among surveyed animals.

Overall, extracted data were organised in 52 epidemiological units for cattle, 35 for sheep and 25 for dogs. The pooled prevalence and its 95% CI for each investigated NUTS1 are reported in Tables [3](#pntd.0008519.t003){ref-type="table"}, [4](#pntd.0008519.t004){ref-type="table"} and [5](#pntd.0008519.t005){ref-type="table"}, respectively for cattle, sheep and dogs. The spatial patterns of CE distributions in the three animal hosts are shown in Figs [3](#pntd.0008519.g003){ref-type="fig"}--[5](#pntd.0008519.g005){ref-type="fig"}.

![Spatial distribution of CE prevalence in cattle.\
Pooled prevalence values at NUTS1 level are visualised with progressively intense colours according to ranges established by Jenks optimization method and manually adjusted for a better results visualisation. Data at country level are reported only if more detailed data at NUTS1 level were not available (source of NUTS shapefiles: Eurostat).](pntd.0008519.g003){#pntd.0008519.g003}

![Spatial distribution of CE prevalence in sheep.\
Pooled prevalence values at NUTS1 level are visualised with progressively intense colours according to ranges established by Jenks optimization method and manually adjusted for a better results visualisation. Data at country level are reported only if more detailed data at NUTS1 level were not available (source of NUTS shapefiles: Eurostat).](pntd.0008519.g004){#pntd.0008519.g004}

![Spatial distribution of *E*. *granulosus s*.*l*. prevalence in dogs.\
Pooled prevalence values at NUTS1 level are visualised with progressively intense colours according to ranges established by Jenks optimization method and manually adjusted for a better results visualisation. Data at country level are reported only if more detailed data at NUTS1 level were not available (source of NUTS shapefiles: Eurostat).](pntd.0008519.g005){#pntd.0008519.g005}

10.1371/journal.pntd.0008519.t003

###### Pooled prevalence at NUTS1 level in cattle populations.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country       NUTS1 code                                  N epidem. units   Years[^a^](#t003fn002){ref-type="table-fn"}   Total positive animals   Total tested animals   Pooled prevalence\   CI95% min\   CI95% max\   References
                                                                                                                                                                            (%)                  (%)          (%)          
  ------------- ------------------------------------------- ----------------- --------------------------------------------- ------------------------ ---------------------- -------------------- ------------ ------------ --------------------------------------------------------------------------------------------------
  **Spain**     ** **                                       **1**                                                           ** **                    ** **                                       ** **        ** **        

                ES2                                         1                 2000--2006                                    683                      40,196                 **1.70**             1.58         1.83         \[[@pntd.0008519.ref034]\]

  **France**    ** **                                       **1**                                                                                                                                                          

                FR0[^b^](#t003fn003){ref-type="table-fn"}   1                 2011                                          4                        138,624                **0.003**            0.001        0.008        \[[@pntd.0008519.ref035]\]

  **Italy**     ** **                                       **37**                                                                                                                                                         

                IT0[^c^](#t003fn004){ref-type="table-fn"}   1                 2009--2010                                    23                       2,699                  **0.85**             0.56         1.27         \[[@pntd.0008519.ref036]\]

                ITC                                         5                 2005--2008                                    1,473                    731,936                **0.22**             0.21         0.23         \[[@pntd.0008519.ref037],[@pntd.0008519.ref038]\]

                ITH                                         6                 2001--2010                                    1,404                    393,848                **0.36**             0.34         0.38         \[[@pntd.0008519.ref038]--[@pntd.0008519.ref040]\]

                ITI                                         6                 1995--2010                                    9,092                    55,358                 **16.69**            16.30        17.08        \[[@pntd.0008519.ref036],[@pntd.0008519.ref038],[@pntd.0008519.ref041]\]

                ITF                                         10                2004--2010                                    1,871                    9,074                  **21.26**            20.41        22.14        \[[@pntd.0008519.ref036],[@pntd.0008519.ref038],[@pntd.0008519.ref042]--[@pntd.0008519.ref045]\]

                ITG                                         9                 2004--2015                                    3,203                    31,182                 **42.61**            41.46        43.78        \[[@pntd.0008519.ref036],[@pntd.0008519.ref038],[@pntd.0008519.ref046]--[@pntd.0008519.ref051]\]

  **Greece**    ** **                                       **2**                                                                                                                                                          

                EL5                                         1                 2009                                          18                       372                    **4.84**             3.07         7.55         \[[@pntd.0008519.ref052]\]

                EL6                                         1                 1999                                          2                        792                    **0.25**             0.06         1.00         \[[@pntd.0008519.ref053]\]

  **Romania**   ** **                                       **11**                                                                                                                                                         

                RO0[^d^](#t003fn005){ref-type="table-fn"}   4                 2001--2012                                    164,939                  864,390                **19.10**            19.02        19.18        \[[@pntd.0008519.ref054]--[@pntd.0008519.ref057]\]

                RO1                                         2                 2008--2011                                    3,233                    8,009                  **40.94**            39.81        40.08        \[[@pntd.0008519.ref058]\]

                RO2                                         2                 2008--2011                                    1,269                    5,127                  **26.04**            24.80        27.33        \[[@pntd.0008519.ref058]\]

                RO3                                         1                 2008--2011                                    1,789                    2,791                  **64.09**            62.30        65.86        \[[@pntd.0008519.ref058]\]

                RO4                                         2                 2003--2011                                    15,750                   87,667                 **18.12**            17.86        18.38        \[[@pntd.0008519.ref058],[@pntd.0008519.ref059]\]

  **Total**                                                 **52**                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NUTS1 codes explanation is provided in Supplementary Information [S3 Table](#pntd.0008519.s005){ref-type="supplementary-material"}. NUTS1 with "0" after the two-letters initials of the country refers to the whole country.

^a^Years refers to the overall time frame of all included studies.

^b^This study was conducted in the South of France, but it was not possible to refer data to precise NUTS2 or NUTS1.

^c^This paper did not differentiate between North-western and North-eastern Italy, reporting an aggregate value for the whole North Italy.

^d^These papers were reporting data from nation-wide surveys involving different areas, but results were presented in an aggregate way.

10.1371/journal.pntd.0008519.t004

###### Pooled prevalence at NUTS1 level in sheep populations.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country       NUTS1 code                                  N epidem. units   Years[^a^](#t004fn002){ref-type="table-fn"}   Total positive animals   Total tested animals   Pooled prevalence (%)   IC95% min\   IC95% max\   References
                                                                                                                                                                                                    (%)          (%)          
  ------------- ------------------------------------------- ----------------- --------------------------------------------- ------------------------ ---------------------- ----------------------- ------------ ------------ ---------------------------------------------------------------------------------------------------
  **Spain**     ** **                                       **1**                                                                                                                                                             

                ES2                                         1                 2000--2006                                    88                       88,369                 **0.10**                0.08         0.12         \[[@pntd.0008519.ref034]\]

  **France**    ** **                                       **1**                                                                                                                                                             

                FR0[^b^](#t004fn003){ref-type="table-fn"}   1                 2010                                          27                       725,903                **0.004**               0.003        0.005        \[[@pntd.0008519.ref035]\]

  **Italy**     ** **                                       **13**                                                                                                                                                            

                ITC                                         1                 2006                                          3                        822                    **0.36**                0.11         1.12         \[[@pntd.0008519.ref037]\]

                ITI                                         2                 1995--2004                                    14,829                   25,225                 **58.09**               57.46        58.72        \[[@pntd.0008519.ref041],[@pntd.0008519.ref060]\]

                ITF                                         1                 2006                                          77                       365                    **21.09**               16.90        25.30        \[[@pntd.0008519.ref045]\]

                ITG                                         9                 1995--2010                                    4,821                    6,998                  **68.50**               67.38        69.59        \[[@pntd.0008519.ref046]--[@pntd.0008519.ref048],[@pntd.0008519.ref061]--[@pntd.0008519.ref065]\]

  **Greece**    ** **                                       **9**                                                                                                                                                             

                EL5                                         4                 2009--2015                                    336                      1,140                  **29.53**               26.95        32.25        \[[@pntd.0008519.ref066]\]

                EL6                                         5                 1999--2015                                    1,080                    6,906                  **30.08**               28.54        31.68        \[[@pntd.0008519.ref053],[@pntd.0008519.ref063],[@pntd.0008519.ref066]--[@pntd.0008519.ref068]\]

  **Romania**   ** **                                       **11**                                                                                                                                                            

                RO0[^c^](#t004fn004){ref-type="table-fn"}   4                 2001--2012                                    78,421                   600,829                **13.16**               13.07        13.25        \[[@pntd.0008519.ref054]--[@pntd.0008519.ref057]\]

                RO1                                         2                 2008--2011                                    2,942                    5,834                  **50.28**               48.99        51.58        \[[@pntd.0008519.ref058]\]

                RO2                                         2                 2008--2011                                    5,672                    12,443                 **45.70**               44.81        46.58        \[[@pntd.0008519.ref058]\]

                RO3                                         1                 2008--2011                                    1,341                    1,951                  **68.73**               66.64        70.75        \[[@pntd.0008519.ref058]\]

                RO4                                         2                 2003--2011                                    8,690                    83,942                 **11.07**               10.84        11.30        \[[@pntd.0008519.ref058],[@pntd.0008519.ref059]\]

  **Total**                                                 **35**                                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NUTS1 codes explanation is provided in Supplementary Information [S3 Table](#pntd.0008519.s005){ref-type="supplementary-material"}. NUTS1 with "0" after the two-letters initials of the country refers to the whole country.

^a^Years refers to the overall time frame of all included studies.

^b^The study was conducted in the South of France, but it was not possible to refer data to precise NUTS2 or NUTS1.

^c^These papers were reporting data from nation-wide surveys involving different areas, but results were presented in an aggregate way.

10.1371/journal.pntd.0008519.t005

###### Pooled prevalence at NUTS1 level in dog populations.

![](pntd.0008519.t005){#pntd.0008519.t005g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country        NUTS1 code   N epidem. units   Years[^a^](#t005fn002){ref-type="table-fn"}   Total positive animals   Total tested animals   Pooled prevalence (%)   IC95% min\   IC95% max\                                   References
                                                                                                                                                                      (%)          (%)                                          
  -------------- ------------ ----------------- --------------------------------------------- ------------------------ ---------------------- ----------------------- ------------ -------------------------------------------- ----------------------------------------------------
  **Portugal**   ** **        **4**                                                                                                                                                                                             

                 PT1          4                 2009--2016                                    1                        1,086                  **0.95**                0.13         6.45                                         \[[@pntd.0008519.ref069]--[@pntd.0008519.ref072]\]

  **Spain**      ** **        **4**                                                                                                                                                                                             

                 ES2          2                 1998--2003                                    106                      1,761                  **11.86**               9.89         14.18                                        \[[@pntd.0008519.ref073],[@pntd.0008519.ref074]\]

                 ES6          2                 2004--2005                                    0                        350                    **0.00**                0.00         0.84[^b^](#t005fn003){ref-type="table-fn"}   \[[@pntd.0008519.ref075],[@pntd.0008519.ref076]\]

  **France**     ** **        **1**                                                                                                                                                                                             

                 FMR          1                 2013--2014                                    3                        259                    **1.16**                0.37         3.53                                         \[[@pntd.0008519.ref077]\]

  **Italy**      ** **        **7**                                                                                                                                                                                             

                 ITC          2                 2003--2006                                    19                       66                     **28.83**               19.20        40.85                                        \[[@pntd.0008519.ref037],[@pntd.0008519.ref078]\]

                 ITH          1                 2012--2017                                    2                        208                    **0.96**                0.24         3.76                                         \[[@pntd.0008519.ref079]\]

                 ITI          1                 2003                                          5                        106                    **4.72**                1.98         10.83                                        \[[@pntd.0008519.ref078]\]

                 ITF          1                 2006                                          36                       113                    **31.86**               23.94        40.97                                        \[[@pntd.0008519.ref045]\]

                 ITG          2                 2003--2005                                    40                       352                    **23.17**               16.47        31.57                                        \[[@pntd.0008519.ref046],[@pntd.0008519.ref080]\]

  **Albania**    ** **        **1**                                                                                                                                                                                             

                 AL0          1                 2009                                          3                        111                    **2.70**                0.87         8.04                                         \[[@pntd.0008519.ref081]\]

  **Kosovo**     ** **        **2**                                                                                                                                                                                             

                 Kosovo       2                 2004--2013                                    10                       809                    **1.53**                0.82         2.82                                         \[[@pntd.0008519.ref082],[@pntd.0008519.ref083]\]

  **Romania**    ** **        **3**                                                                                                                                                                                             

                 RO1          1                 2008                                          364                      1,892                  **19.24**               17.52        21.08                                        \[[@pntd.0008519.ref084]\]

                 RO3          1                 2011                                          8                        86                     **9.30**                4.72         17.51                                        \[[@pntd.0008519.ref085]\]

                 RO4          1                 2011                                          4                        46                     **8.67**                3.30         20.97                                        \[[@pntd.0008519.ref085]\]

  **Bulgaria**   ** **        **2**                                                                                                                                                                                             

                 BG3          1                 2014                                          0                        40                     **0.00**                0.00         7.33[^b^](#t005fn003){ref-type="table-fn"}   \[[@pntd.0008519.ref086]\]

                 BG4          1                 2014                                          0                        40                     **0.00**                0.00         7.33[^b^](#t005fn003){ref-type="table-fn"}   \[[@pntd.0008519.ref086]\]

  **Cyprus**     ** **        **1**                                                                                                                                                                                             

                 CY0          1                 2001                                          184                      6,489                  **2.84**                2.46         3.27                                         \[[@pntd.0008519.ref087]\]

  **Total**                   **25**                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NUTS1 codes explanation is provided in Supplementary Information [S3 Table](#pntd.0008519.s005){ref-type="supplementary-material"}. NUTS1 with "0" after the two-letters initials of the country refers to the whole country.

^a^Years refers to the overall time frame of all included studies.

^b^When no animal resulted positive, the maximum expected prevalence value was calculated theoretically, considering a population N = 10,000 and the overall sampling size n (i.e. n = 350 in ES6 and n = 40 in BG3 and BG4).

Discussion {#sec011}
==========

The burden of infection with *E*. *granulosus s*.*l*., in both humans and animals, is difficult to ascertain, due to the clinical characteristics of CE in humans (a chronic, often asymptomatic or pauci-symptomatic infection, affecting mostly rural populations, with a patchy distribution on the territory) and the perceived low impact on health and productivity in animals. In this systematic review, we aimed to provide a picture of the recent epidemiological situation of human and animal (cattle, sheep and dog) infection in European Mediterranean and Balkan countries, based on published literature, and to investigate the similarities in their patterns. These data may help highlight the importance of this neglected infection even in a high-resource area like Europe and define gaps in knowledge regarding its distribution. Although we did not perform a formal quality and bias assessment of the publications included, the results of our review highlight the presence of a paucity of human prevalence studies, the heterogeneity of data, and the patchy geographical coverage.

Results obtained from the analysis of human-based studies on CE highlight the paucity of prevalence studies, the heterogeneity of incidence data that could be retrieved for the analysis (average annual incidence rates at NUTS1 level ranged from 0.10 to 7.74 per 100,000), and the patchy geographical coverage of the studies, with lack of such data especially for the Balkans. As mentioned, CE is a neglected, chronic infection often asymptomatic or pauci-symptomatic for a long time or even indefinitely. The population of individuals with CE can be schematically described as a pyramid composed of: i) the "tip" formed by cases reaching medical attention and hospitalized, therefore included in official HDR-based statistics; ii) a "stratum" of cases reaching medical attention but not requiring hospitalization and therefore only variably captured in medical records; and iii) the "basis" formed by the likely large proportion of cases never reaching medical attention. This last portion of individuals with CE can only be quantified using population-based screening campaigns, which are extremely scant in the retrieved published literature. Consequently, prevalence and clinical-based studies are complementary and not mutually exclusive, not only for the understanding of CE epidemiology on a territory, but also for burden of disease estimates and public health evaluations. Indeed, clinically relevant cases (i.e. where the infection has a health impact requiring treatment) can be present in all above-mentioned categories \[[@pntd.0008519.ref010],[@pntd.0008519.ref088]\], due to the proteiform clinical characteristics of CE and its neglected status, with generally poor awareness of both at-risk populations and health care personnel, and consequent misdiagnosis and underreporting. Concerning clinical-based studies, major limitations of most studies for the understanding of CE epidemiology are their heterogeneity in terms of type of cases included (such as all cases reaching medical attention, or hospitalized cases, or surgically confirmed ones, or only residents in a particular area) and the frequent lack of reporting of the at-risk population to which the incidence estimate refers. Furthermore, being CE a chronic and complex infection requiring long-term follow-up, distinction between incidence of first clinical diagnoses and incidence simply calculated using retrospective clinical records would be important but was seldom specified. In this light, at least to capture all cases reaching medical attention, it would be pivotal to implement a compulsory notification system, including both hospitalized patients and outpatients. The European Register of CE (ERCE) \[[@pntd.0008519.ref089]\], if adopted at national level by health authorities, could represent a suitable platform for such a system.

For what concerns the spatial distribution of human CE, the results of our study, granted the absence of data from many Balkan countries, indicate Southern (ITF) and insular (ITG) Italy, Spain, and Eastern Europe (Bulgaria and Romania) as the most affected areas, in line with other recent narrative reviews \[[@pntd.0008519.ref001]\] and official WHO data \[[@pntd.0008519.ref090]\]. Minor differences from these figures are probably due to the different criteria used for data inclusion. The large differences between minimum and maximum incidence estimate calculated for some NUTS1 derive either from differences over time for the same area (e.g. Stara Zagora region in Bulgaria--BG3) or from both differences in the values of included NUTS2 and across the investigated period, such as in Southern and insular Italy, and in Central Spain (ES4). Also, the different inclusion criteria for cases series (all clinically observed cases or hospitalized cases) and the frequently unclear definition of the population at risk had an important impact on the estimation of incidence rate, as evidenced by the studies in North-eastern (ES2) and Central Spain \[[@pntd.0008519.ref013]--[@pntd.0008519.ref015],[@pntd.0008519.ref017]\].

Also the data on animal infection are not uniformly distributed in the study area, as demonstrated by the differences in number of epidemiological units investigated in selected countries, with Italy and Romania generally representing the most investigated countries. As for human studies, data for cattle and sheep were not available for the Balkan area. Besides, few and spatially limited studies on animal hosts were retrieved for the Iberian Peninsula.

Studies on intermediate hosts showed a good level of homogeneity in methodology, being all based on retrospective slaughterhouse surveys, but had ample variability in results. In all investigated populations, at least one positive animal was found, and pooled prevalence values at NUTS1 level varied from 0.003% to 64.09% in cattle, and from 0.004% to 68.73% in sheep. All animals slaughtered in a given area/abattoir were generally considered as the population at risk, and only in a few studies young animals were excluded. Most of the studies were based on the passive surveillance activity (meat inspection) routinely implemented in slaughterhouses, thus most likely ensuring sufficiently similar diagnostic performances among all investigations. This aspect suggests that data extracted from these papers are comparable for the whole study area. Since the population at risk (denominator) was reported in all studies, we were able to calculate the pooled prevalence for each NUTS1. This provided a weighted value, accounting for individual study weights due to different sample sizes, in the investigations conducted in the same epidemiological unit. Higher prevalence values were similarly found for sheep and cattle in Central (ITI), Southern and insular Italy, and in Romania (\>10%), whereas high rates were encountered only for sheep in Greece. Northern Italy (ITC and ITH) and France reported prevalence values below 1%, confirming their status of hypo-endemic areas \[[@pntd.0008519.ref001]\].

Dog populations were mostly investigated through cross-sectional surveys, showing mean prevalence values ranging from 0 to 31.86%. The differences in prevalence rates reflect the variability among areas, and the distribution pattern only partly resembles that of human incidence (Figs [1](#pntd.0008519.g001){ref-type="fig"} and [4](#pntd.0008519.g004){ref-type="fig"}). However, these differences can be due also to the use of different investigation approaches, both in terms of diagnostic techniques and specific target population. Most studies targeted at-risk dogs (i.e. with higher probability of accessing raw infected offal of intermediate hosts) such as sheep dogs or free-ranging dogs, since their main objective was to find positive dogs. Therefore, in consideration of the general heterogeneity of inclusion criteria of dogs among these investigations, the comparison of results is difficult. Besides, the ample variability of diagnostic techniques used by different studies is alone sufficient to hamper any possibility of comparing data among areas. In some cases, studies using coproELISA techniques showed an unexpectedly high prevalence (e.g. North-western Italy---ITC), suggesting a possible cross-reactivity problem, as already described for this technique and generally occurring when infection with other Taenidae, particularly *Taenia hydatigena*, is common in the area \[[@pntd.0008519.ref091]\].

In the present study we investigated differences in spatial distribution of *E*. *granulosus s*.*l*., referring data extracted from the available literature to an artificial epidemiological unit (one NUTS2 in one year) created *ad hoc*. The intention was to make extracted data as much homogeneous as possible in terms of investigated population, allowing a fair comparison among areas. Actually, data obtained from literature were extremely variable from different points of view, including the real extension of studied populations (e.g. only a limited area/population of the NUTS2 was investigated in some publications). In the case of cross-sectional studies, we addressed the problem of limited homogeneity among studies in animals (all papers) and humans (only 2 papers), calculating the pooled prevalence, which accounts for the differences in the investigated populations size (i.e. sampling fraction). Coming to retrospective case series studies in humans reporting incidence data (all but two papers), it should be noted that these studies usually considered all the inhabitants of the area under investigation as the population at risk, which therefore generally consisted of hundreds thousands or millions individuals. In our review, the single-year figure for human population at risk could be estimated only in the 87 epidemiological units of the 4 papers where incidence value was associated with the number of new cases for each year. In these units the population at risk ranged from a minimum of 73,529 to a maximum of 6,250,000 persons, but it was comprised in most cases (75%; 66/87) between 500,000 and 3,000,000.

In consideration of the chronic nature of CE in humans, we decided that it was of little value to attempt the identification of overall temporal trends in the time frame fixed for our literature search. Coming to infection in animal hosts, few areas were investigated for more than two consecutive years. As a consequence, we did not compare incidence and prevalence data among different periods in the years (1995--2019) covered by our review. However, it is worth noting that some multi-year studies described such kind of temporal trends, usually showing a decreasing trend of the disease burden in humans \[[@pntd.0008519.ref014],[@pntd.0008519.ref017],[@pntd.0008519.ref021],[@pntd.0008519.ref032]\], whereas in animals both decreasing and stable trends were reported \[[@pntd.0008519.ref034],[@pntd.0008519.ref041],[@pntd.0008519.ref065]\].

The inhomogeneous geographical coverage of human and animal studies prevented a formal analysis of the relation between human and animal infection epidemiology. However, the geographical distribution of *E*. *granulosus s*.*l*. infection in different territories of European Mediterranean and Balkan countries presents high similarities between human and animal hosts, as shown by the four maps. In particular, both bovine and ovine prevalence patterns parallel quite well human incidence distribution, at least for the NUTS1 where data are available for all species. In our literature search, few papers reported data from both humans and animals, and only three investigated the correlation between human and animal data, reporting that the reduction in infection rates in dogs and livestock corresponded to a similar decline in human CE incidence \[[@pntd.0008519.ref013],[@pntd.0008519.ref015],[@pntd.0008519.ref026]\]. Our analysis did not allow for a statistically based inference on the relation between prevalence data in animal hosts and human incidence, but results from NUTS investigated for both human and animal infection suggest that a relation can be assumed. It is well known that in Mediterranean and Balkan countries the transhumant sheep farming is considered as the main driver for *E*. *granulosus s*.*l*. maintenance \[[@pntd.0008519.ref092],[@pntd.0008519.ref093]\]. However, in our results, bovine data showed a more similar pattern to human data compared to sheep, suggesting its potential role as sentinel species for estimating the risk for humans to get infected with CE, in areas where both livestock breeding is practiced, as previously hypothesized \[[@pntd.0008519.ref043],[@pntd.0008519.ref079]\]. This could be in part due to the more similar condition of the human and bovine host in respect to CE and its diagnosis, compared to sheep, i.e. a longer average lifespan of cattle allows for a more extended time from infection up to the moment when this is evidenced at slaughterhouse. Since *E*. *granulosus sensu strictu* G1-G3 are the genotypes mainly affecting bovines in Europe \[[@pntd.0008519.ref094]\], the higher similarities in epidemiological features of infection between cattle and humans may be also due to their common role of accidental intermediate hosts for these genotypes. A quantitative description of circulating genotypes could help in a better interpretation of the relation between human and animal prevalence data. This information is available at global level \[[@pntd.0008519.ref095]\] or more specifically in other geographical context \[[@pntd.0008519.ref096]\], but not for the areas included in our review. A more detailed description was not attempted in this study, because of the paucity of relevant data in the included papers on animal infection and the absence of such information from studies on humans.

It is worth mentioning that in this review we did not include data of livestock intermediate hosts other than sheep and cattle that can have a role in the human infection epidemiology, such as swine and goats. This decision was based on the observation that other hosts seem of lower relevance for the epidemiology of human CE in the investigated geographical area \[[@pntd.0008519.ref001], [@pntd.0008519.ref094]\]. Equally, we did not address *E*. *granulosus s*.*l*. infection in wild definitive and intermediate hosts such as sylvatic canids and wild boars or wild ungulates. However, the investigation of the epidemiology of CE in other animals, especially livestock, is surely of interest and should be envisaged as a future, complementary systematic review.

Finally, the results of our analysis highlight the notorious problem of underreporting of CE in humans. As an example, if we consider the recent work by Piseddu and colleagues examining HDR for CE in Italy from 2001 to 2014 \[[@pntd.0008519.ref004]\], the median of CE hospitalizations per year was 848. This figure alone roughly equals all cases of echinococcosis (both cystic and alveolar echinococcosis) reported by all Member States at European level yearly \[[@pntd.0008519.ref006]\] but Italy does not even report HDR data at European level. Substantial underreporting is also indicated by data from other countries; for example in 2013 in Romania only 55 CE cases were reported in official European statistics for the whole country \[[@pntd.0008519.ref097]\], while one hospital alone in the capital, for the same year, recorded 104 CE cases \[[@pntd.0008519.ref010]\].

Also data on animal infection extracted from the reviewed literature showed evident differences with official European Union yearly reports, where a specific table on number of animals positive/tested for *E*. *granulosus s*.*l*. has been included since 2015 \[[@pntd.0008519.ref006],[@pntd.0008519.ref098]--[@pntd.0008519.ref100]\]. As an example, in these reports, the prevalence reported for sheep in Greece was constantly \<2%, whereas values near to 30% were found in our review. Similarly, values generally \<5% are officially reported for Italian sheep, whereas half of the Italian NUTS included in the present study showed pooled prevalence higher than 50%.

In conclusion, this systematic review provides a rigorous summary of the epidemiological situation of *E*. *granulosus s*.*l*. infection in humans and in selected domestic animals, based on published literature, demonstrating that prevalence values for bovine intermediate host parallel quite well human incidence. While studies on animal intermediate hosts were sufficiently well defined and homogeneous, studies on humans were extremely heterogeneous and lacking important information, such as the precise definition of the population at risk, inclusion criteria for cases, and sometimes also the number of newly diagnosed cases. Also, prevalence studies were extremely scant. The implementation of new studies on human incidence and prevalence and bovine prevalence, appropriately defined in their methodology and covering the geographical areas still not investigated, could help in completing the picture already drafted by our review. The results of our study show the importance of this neglected infection in the study area and strongly prompt public health authorities to implement surveillance strategies for both human and animal infection.
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Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: The objective of the study are clearly defined, the study design is appropriate, the sample size (papers for a systematic review) sufficient to address the hypothesis being tested, and the statistical analysis is correct. There are no concerns on ethical and regulatory requirements.

Reviewer \#2: Objectives are clearly articulated. Study design is appropriate and statistics are correct for the analysis performed

Reviewer \#3: The first sentence of the Materials and Methods refers to "the research question". However, a research question is not explicitly stated.

Please indicate why the specific databases (and web search engines) were chosen and why the original search dates differed between sites. It is also not clear what \#20-\#24 refer to in the Embase search strategy (S1 text).

Please elaborate on why only the first 500 search results were considered for the Google Scholar, Scopus, and Open Grey searches? Where these sorted by relevance or date?

What is meant by "publication status" (line 111)?

It appears that data could be included from 1980 onward, but only articles published after 2000 were included in the review. How do the authors justify the 1980 data cutoff (line 115)?

The authors need to provide an overview of the NUTS system and elaborate on what constitutes the NUTS1 and NUTS2 levels. Without this information in the main text, the paper becomes very difficult to follow.

I would suggest that the NUTS1 codes be included in the actual paper (or the NUTS1 codes swapped for the region names in the tables).

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: The analysis presented match the analysis plan. The results are clearly presented including tables and maps of good quality for clarity.

Reviewer \#2: Results are clearly and completely presented. Figures and tables are clear and well presented

Reviewer \#3: Since data appear to be included from 1980 onward, it would be helpful if the tables provided the time frames encompassed by the included studies.

It appears that, in many publications, disease frequency (e.g., incidence) was calculated by the original authors. Did the review authors use any method to assess level of bias in the included articles?

Figure 5- I assume the authors mean E. granulosus s.l. prevalence and not CE prevalence since dogs are infected with the adult form of the parasite.

Figures- prevalence and incidence bins are not mutually exclusive (e.g., would an area where the prevalence in cattle is 4.0% go in the 0.0-4.0 bin or the 4.0-10.0 bin).

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: The conclusions are supported by the data presented. However, the limitation of the analysis is not clearly described. The topic is of public health importance and the public health relevance is well addressed.

Reviewer \#2: See summary and general comments

Reviewer \#3: The authors discuss how differences in the clinical presentation of CE patients (e.g., surgical patients versus patients being treated medically or detected incidentally) impact the available data. That being said, it would be helpful if data type was included in table 1. Along those same lines, inclusion of diagnostic technique would assist with understanding the values produced for definitive hosts (table 5)?

Again, please clarify the time frame for the data included in the review (line 432).

The authors spend quite a bit of the Discussion trying to explain relationships that they earlier state could not be evaluated (e.g., in support of the authors' previously published hypothesis regarding the use of cattle as sentinel species). Therefore, they may want to temper the language somewhat.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: Minor revision

Reviewer \#2: (No Response)

Reviewer \#3: Title: It appears that the authors not only evaluated cystic echinococcosis (i.e., infection with the larval form of the parasite), but also adult parasite infection in definitive hosts. This is not reflected in the title.

Abstract: NUTS1, NUTS2, and epidemiological unit are not well defined in the abstract. A clearer link needs to be made between the presented principal findings and the conclusion that Italy, Spain, and Eastern Europe are the most affected areas.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: The manuscript PNTD-D-20-00593 by Tamarozzi et al. titled "Epidemiological distribution of human and animal cystic echinococcosis in European Mediterranean and Balkan coutries: a Systematic Rewier" describes the results obtained from a systematic literature review on Echinococcus granulosus in humans and animals. The aim of this study is to give an overview on the distribution and epidemiology of cystic echinococcosis in Europe, and specifically in European Mediterranean and Balkan countries, where this disease is endemic. For this purpose, the authors considered all possible studies that could help to answer the research question. Thus, cross-sectional and longitudinal studies, as well as case series, reporting prevalence or incidence of human or animal (ovine, bovine, and canine) E. granulosus s.l. infection were included. To ensure maximum data accuracy, only papers/studies reporting the species of Echinococcus investigated, the number of people/animals surveyed, the number of positive cases, details about the methodology of diagnosis and the geographical site were included. Each data obtained, separated for host species, was then referred to a specific NUTS (Nomenclature of Territorial Units for Statistics). The work is presented according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

The topic is of interest due to the impact of cystic echinococcosis (CE) on human and animal health, but also for the economic losses associated. There is a growing interest on CE and a comprehensive review of its distribution in definitive and intermediate hosts in endemic areas, as those described in the work, could improve the targeting of control measures and to enhance the cost-effectiveness of integrated disease control programmes for E. granulosus.

Thus, I recommend the publication of the paper in PLOS Neglected Tropical Diseases after minor revisions. The paper is well written, the questions posed by the authors are well defined, the methods appropriate, and the results, discussion and conclusions well balanced and adequately supported by the data.

GENERAL COMMENTS

\- Authors should explain why they didn't consider animal intermediate hosts other than cattle and sheep, e.g. swine and equids. Furthermore, the role of sylvatic canids and wild intermediate hosts (e.g. wild boar and wild ungulates) should be considered in the epidemiology of E. granulosus.

\- I was wondering how the authors have treated farm prevalence data in their analysis.

\- I would suggest the authors to add data on genotypes of E. granulosus if available from the studies used for their review.

\- The Authors often mention the limitation of the studies used in their review. But wat about the limitation of their approach?

\- From a practical point of view, I would suggest to emphasize how the maps and the outcome of the review will be transferred to policy makers and stake holders, in order to improve surveillance of this important neglected disease as well as in order to plan effective control measures against E. granulosus

SPECIFIC COMMENTS

\- Line 94: At the end of the introduction, the authors explain the aim of this work, specifying that the systematic review was carried out between 1980 and 2019, whereas in the abstract they mention "between 2000 and 2019". Moreover, since papers before 2000 were not considered in the review, I would suggest to change to "between 2000 and 2019" throughout the study.

\- Line 107: Please change "Echinococus" to "Echinococcus".

\- Line 117, Please provide a reference for PRISMA

Reviewer \#2: In general, this is a very interesting review on the status of CE in human and animla hosts, and gives a good idea on the underrreporting of official data. The highlights of this systematic review (underreporting, centinel animals and geograpical distribution) are of importance not only for the scientific community, but also for the policy makers.

Minor comments: Authors should doublé-check if articles on animal CE refer to animals only slaughtered in a given geographical area or breeded/fed in the geographical area or reference for each article. Slaughterhouses in EU are now big and are usually \"specialized\" in a specific animal species, and usually receive animals of that species from all geographical regions inside the country. Geographical origin (and not place of slaughter) of the CE infected animals should be cross-checked.

A second question of concern is the age of animals. Sheep reaching slaughetrhouses and subjected to inspection are in many cases very young animals. Maybe this could explain the best matching between human-cow numbers and not between human-sheep numbers. This should be commented in the text

Reviewer \#3: This is a systematic review looking at Echinococcus granulosus senu lato infection in humans and animal hosts in Mediterranean and Balkan countries. The authors use the Nomenclature of Territorial Units for Statistics (NUTS) to analyze and present their findings. However, the NUTS system (and the reason for using this system) is not well described, making it difficult for the reader to interpret what the findings mean from a country level and control perspective.
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Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods>
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18 Jun 2020

Dear Prof. Cassini,

Thank you very much for submitting your manuscript \"Epidemiological distribution of Echinococcus granulosus s.l. infection in human and domestic animal hosts in European Mediterranean and Balkan countries: a Systematic Review\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

There is a minor suggestion. For human incidence, authors should always use \"annual incidence per 100,000\" rather than \"incidence per 100,000\". This is to standardize disease reporting and to ensure the incidence is reported as annual incidence and not over some other period of time.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Paul Robert Torgerson

Guest Editor

PLOS Neglected Tropical Diseases

Adriano Casulli

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

There is a minor suggestion. For human incidence, authors should always use \"annual incidence per 100,000\" rather than \"incidence per 100,000\". This is to standardize disease reporting and to ensure the incidence is reported as annual incidence and not over some other period of time

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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25 Jun 2020

Dear Prof. Cassini,

We are pleased to inform you that your manuscript \'Epidemiological distribution of Echinococcus granulosus s.l. infection in human and domestic animal hosts in European Mediterranean and Balkan countries: a Systematic Review\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Paul Robert Torgerson

Guest Editor

PLOS Neglected Tropical Diseases

Adriano Casulli

Deputy Editor

PLOS Neglected Tropical Diseases
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3 Aug 2020

Dear Prof. Cassini,

We are delighted to inform you that your manuscript, \"Epidemiological distribution of Echinococcus granulosus s.l. infection in human and domestic animal hosts in European Mediterranean and Balkan countries: a Systematic Review,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases
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